Evidence map›Paper›PMID 26191232›Full record

ArticleInternational journal of clinical and experimental pathology2015

S4646 polymorphism in CYP19A1 gene is associated with the efficacy of hormone therapy in early breast cancer.

Xiying Shao, Jinwei Cai, Yabing Zheng, Jiwen Wang, Jianguo Feng, Yuan Huang, Lei Shi, Zhanhong Chen, Yong Guo, Xiaojia Wang

Open access · greenAbstract readComparative Study
PubMed Full text at PMC
In one paragraph

Article in International journal of clinical and experimental pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Trial
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Xiying ShaoDepartment of Medical Oncology, Affiliated Zhejiang Cancer Hospital of Zhejiang Chinese Medical University Hangzhou, Zhejiang Province, China.
Jinwei CaiDepartment of Oncology, People's Hospital of Kecheng District Quzhou, Zhejiang Province, China.
Yabing ZhengDepartment of Medical Oncology, Affiliated Zhejiang Cancer Hospital of Zhejiang Chinese Medical University Hangzhou, Zhejiang Province, China.
Jiwen WangCancer Research Institute, Zhejiang Cancer Hospital Hangzhou, Zhejiang Province, China.
Jianguo FengCancer Research Institute, Zhejiang Cancer Hospital Hangzhou, Zhejiang Province, China.
Yuan HuangDepartment of Medical Oncology, Affiliated Zhejiang Cancer Hospital of Zhejiang Chinese Medical University Hangzhou, Zhejiang Province, China.
Lei ShiDepartment of Medical Oncology, Affiliated Zhejiang Cancer Hospital of Zhejiang Chinese Medical University Hangzhou, Zhejiang Province, China.
Zhanhong ChenDepartment of Medical Oncology, Affiliated Zhejiang Cancer Hospital of Zhejiang Chinese Medical University Hangzhou, Zhejiang Province, China.
Yong GuoDepartment of Medical Oncology, The First Affiliated Hospital of Zhejiang Traditional Chinese Medical University Hangzhou, Zhejiang Province, China.
Xiaojia WangDepartment of Medical Oncology, Affiliated Zhejiang Cancer Hospital of Zhejiang Chinese Medical University Hangzhou, Zhejiang Province, China.
Zhejiang Chinese Medical University · CNZhejiang Cancer Hospital · CNQuzhou City People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe aim was to verify the potential association between CYP19A1 genetic polymorphisms and clinical outcome of hormone therapy in hormone receptor (HR)-positive early breast cancer.

methodsGenotyping for CYP19A1 rs4646 (C/A) polymorphism was performed on 287 women with HR-positive early breast cancer. Associations were evaluated between CYP19A1 rs4646 genotypes and disease-free survival (DFS).

resultsTotally, women with the minor allele (AA or AC) had an improved DFS when compared with those carrying the homozygous common allele (CC) (AA or AC vs. CC: 62.7 months versus 55.6 months; Hazard ratio (HR), 0.745; 95% CI, 0.562-0.988; P=0.04). The difference was further demonstrated by multivariate analyses (HR, 0.681; 95% CI, 0.506-0.917; P=0.011). In premenopausal women, AA genotype was associated with a prolonged DFS (AA versus CC or AC: 98.2 months versus 56.2 months; HR, 0.425; 95% CI, 0.198-0.914; P=0.024). In addition, women with the A allele had an improved DFS when compared with those carrying the homozygous C allele (AA or AC vs. CC: 62.7 months versus 55.6 months; HR, 0.709; 95% CI, 0.516-0.975; P=0.033). These findings were further confirmed by the Cox regression model (HR, 0.336, 0.670; 95% CI, 0.160-0.836, 0.479-0.938; P=0.017, 0.019). In postmenopausal women, rs4646 genotypes were significantly associated with DFS (AA versus AC versus CC: 32.7 months versus not reached versus 56.3 months; P=0.011). Women carrying AA variant had a poorer DFS than those with CC or AC genotypes (32.7 months versus 70.6 months; HR, 3.613; 95% CI, 1.380-9.457; P=0.005). Furthermore, being adjusted by the patients features in multivariate analyses, AA genotype remained an independent prognostic factor for DFS (HR, 3.614; 95% CI, 1.308-9.991; P=0.013).

conclusionsThe homozygous minor allele (AA) of CYP19A1 rs4646 is significantly associated with improved clinical outcome of hormone therapy in premenopausal HR-positive early breast cancer patients, but with a worse impact on postmenopausal women. The findings are novel, if confirmed, genotyping for CYP19A1 rs4646 polymorphism may provide predictive information for better selection of endocrine treatment.

Indexed as

Polymorphism, Single NucleotideAdultAgedAntineoplastic Agents, HormonalAromataseBreast NeoplasmsChi-Square DistributionDisease-Free SurvivalFemaleGene FrequencyHeterozygoteHomozygoteHumansKaplan-Meier EstimateMiddle AgedMultivariate AnalysisAntineoplastic Agents, HormonalAromataseCYP19A1 protein, humanaromataseBreast cancergenetic polymorphismspredictive role

Identifiers

PMID26191232
PMCPMC4503103
OpenAlexW1033583922

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.